Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

The Market Herald10-07

Sydney-based drug development company Nyrada Inc (ASX:NYR) has completed an in vivo micronucleus study on rats which has supported expectations of safety for its NYR-BI03 drug candidate – particularly...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473685119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-07 07:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473685119","market":"us","top_or_hot":-1,"title":"Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03","media":"The Market Herald","content":"<div>\n<p>Sydney-based drug development company Nyrada Inc (ASX:NYR) has completed an in vivo micronucleus study on rats which has supported expectations of safety for its NYR-BI03 drug candidate – particularly...</p>\n\n<a href=\"https://themarketonline.com.au/nyrada-rat-study-shows-no-genotoxicity-in-brain-injury-drug-nyr-bi03-2024-10-07/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNyrada rat study shows no genotoxicity in brain injury drug NYR-BI03\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-07 07:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/nyrada-rat-study-shows-no-genotoxicity-in-brain-injury-drug-nyr-bi03-2024-10-07/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sydney-based drug development company Nyrada Inc (ASX:NYR) has completed an in vivo micronucleus study on rats which has supported expectations of safety for its NYR-BI03 drug candidate – particularly...</p>\n\n<a href=\"https://themarketonline.com.au/nyrada-rat-study-shows-no-genotoxicity-in-brain-injury-drug-nyr-bi03-2024-10-07/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NYR.AU","symbol_name":"NYRADA INC-CDI","start_time":0,"source_url":"https://themarketonline.com.au/nyrada-rat-study-shows-no-genotoxicity-in-brain-injury-drug-nyr-bi03-2024-10-07/","article_id":"2473685119","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473685119","pubTimestamp":1728256560,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Sydney-based drug development company Nyrada Inc  has completed an in vivo micronucleus study on rats which has supported expectations of safety for its NYR-BI03 drug candidate – particularly in terms of genetic damage – ahead of Phase 1 human trials later this year.The study – completed as part of Nyrada’s brain injury program Good Laboratory Practices  – found there was no increase in markers of genotoxicity in treated animals compared with control treated animals.NYR-BI03 is being developed to treat both stroke and traumatic brain injury , and these results follow on from news in February that a preclinical stroke study had shown the drug to have achieved a statistically significant neuroprotective effect, rescuing 42% of brain tissue in the penumbra region of treated animals.In October, a preclinical coronary heart disease study demonstrated that the drug bestowed an 86% cardioprotection effect following myocardial ischemia-reperfusion injury, with this being statistically signific","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"NYR.AU":"NYRADA INC-CDI","TBI":"TrueBlue","BK4130":"人力资源与就业服务","GLP":"全球合伙","BK4590":"PTP","BK4144":"石油与天然气的储存和运输","BK7096":"制药"},"translate_title":"Nyrada大鼠研究显示脑损伤药物NYR-BI03无遗传毒性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1,"NYR.AU":1,"TBI":1},"content_text":"Sydney-based drug development company Nyrada Inc (ASX:NYR) has completed an in vivo micronucleus study on rats which has supported expectations of safety for its NYR-BI03 drug candidate – particularly in terms of genetic damage – ahead of Phase 1 human trials later this year.\nThe study – completed as part of Nyrada’s brain injury program Good Laboratory Practices (GLP) – found there was no increase in markers of genotoxicity in treated animals compared with control treated animals.\nNYR-BI03 is being developed to treat both stroke and traumatic brain injury (TBI), and these results follow on from news in February that a preclinical stroke study had shown the drug to have achieved a statistically significant neuroprotective effect, rescuing 42% of brain tissue in the penumbra region of treated animals.\nIn October, a preclinical coronary heart disease study demonstrated that the drug bestowed an 86% cardioprotection effect following myocardial ischemia-reperfusion injury, with this being statistically significant.\nOnce all GLP studies are complete, Nyrada will move on to submitting a Human ResearchEthics Application with the expectation of commencing its first in human Phase I clinical trial in late 2QFY2025 (quarter ending December 2024).\nNyrada has been trading at 10 cents.\nJoin the discussion: See what HotCopper users are saying about Nyrada Inc and be part of the conversations that move the markets.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473685119"}